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Abstract. To define and differentiate relevant aspects of blood–brain barrier transport and distribution in
order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the
rate and extent of brain drug delivery are described and illustrated with relevant data, with special
emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be
comprehensively described using three parameters: Kp,uu (concentration ratio of unbound drug in brain
to blood), CLin (permeability clearance into the brain), and Vu,brain (intra-brain distribution). The
permeability of the blood–brain barrier is less relevant to drug action within the CNS than the extent of
drug delivery, as most drugs are administered on a continuous (repeated) basis. Kp,uu can differ between
CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios
(Kp), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger
range (up to at least 20,000-fold difference). Methods that measure the three parameters Kp,uu,C L in, and
Vu,brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes.
KEY WORDS: blood–brain barrier; brain penetration; drug delivery; permeability clearance; unbound
concentration.
INTRODUCTION
For central drug effects to occur, the drug must first be
delivered to the brain. Because of the properties of the blood–
brain barrier (BBB), researchers accept a high likelihood of
failure when developing drugs for brain delivery (1,2).
Methods for investigating drug candidates in this field, from
in vitro to in situ and in vivo, are under evaluation (1,3–13).
However, confusion remains, and an intense debate is cur-
rently raging regarding how to interpret the results obtained
and which methods to use to select candidates for central
nervous system (CNS) action (14–16). The lack of success
in this respect to date might be due to a lack of common
understanding regarding which processes and properties are
most relevant to successful brain drug delivery. In order to
interpret in vivo results correctly, the various processes
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ABBREVIATIONS: Atot,brain, Total amount of drug in brain including
blood; Abrain, Total amount of drug in brain excluding blood; Acell, Total
amount of drug associated with brain cells; ABCG2, Breast cancer
resistance protein, same as BCRP; AUCtot,brain, Area under the curve
of total concentrations in brain; AUCtot,plasma, Area under the curve of
total concentrations in plasma; AUCu,brain, Area under the curve of
unbound concentrations in brain; AUCu,plasma, Area under the curve
of unbound concentrations in plasma; BBB, Blood–brain barrier;
Bcrp, Breast cancer resistance protein, same as Abcg2; BCSFB,
Blood–cerebrospinal fluid barrier; BEI, Brain efflux index; BUI,
Brain uptake index; Cblood, Total concentrations in whole blood; Ci,
Concentrations in a hypothetical brain compartment; Cu,cell, Unbound
concentration in the brain ICF; Ctot,ss,brain, Totalconcentrationsinbrain
at steady state; Ctot,ss,plasma, Total concentrations in plasma at steady
state; Cu,brainISF, Unbound concentrations in brain ISF; Cu,plasma,
Unbound concentrations in plasma; Cu,ss,brainISF, Unbound con-
centrations in brain ISF at steady state; Cu,ss,plasma, Unbound
concentrations in plasma at steady state; CLi, Intercompartmental
clearance; CLin, Influx clearance into the brain; CLout, Efflux
clearance from the brain; CNS, Central nervous system; CSF,
Cerebrospinal fluid; fu,brain, Fraction unbound drug in brain; fu,r,
Fraction unbound in brain except for ISF (remainder); ICF,
Intracellular fluid; ISF, Interstitial fluid, equal to extracellular fluid
not including plasma; Kin, Brain uptake clearance (iv injection
technique); Kout, Brain efflux clearance; Kp, Total brain/plasma
concentration ratio at steady state; Kp,u, Total brain/ unbound
plasma concentration ratio at steady state; Kp,uu, Unbound brain/
unbound plasma concentration ratio at steady state; Log BB,
Logarithm of the ratio of total steady-state concentration in brain
to blood at a given time point; Oatp2, Organic anion transporter
peptide 2; Oat3, Organic anion transporter 3; Pgp, P-glycoprotein;
PS, Permeability surface area product; Vblood, Physiological volume
of blood per gram brain; VI, Apparent volume of distribution in a
peripheral brain compartment; VISF, Physiological volume of brain
ISF; Vcell, Physiological volume of the brain cells; Vu,brain, Apparent
unbound volume of distribution in brain.
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The present paper therefore addresses the pharmacokinetics
of drug transport into, within, and out of the brain.
A basic assumption in pharmacokinetics is that unbound
drug concentrations are equal on both sides of a physiological
membrane at steady state. The contributions of active influx
and/or efflux, and the presence of tight junctions in the
membrane, mean that the BBB deviates from this assumption
and behaves differently from most other membranes in the
body. Metabolism within the CNS, and/or drug transport to
the cerebrospinal fluid (CSF) via interstitial fluid (ISF) bulk
flow, may also contribute to differing unbound drug concen-
trations on each side of the BBB.
It is generally accepted that it is the unbound drug that
exerts the physiological effect. The comparative importance
of unbound drug concentrations in different brain compart-
ments [ISF or intracellular fluid (ICF)] will depend on where
the relevant receptors are situated. If the drug in question is
actively transported across the cell membrane, brain ICF
concentrations could be expected to differ from brain ISF
concentrations. There is currently no direct method of study-
ing intracellular unbound drug concentrations in the brain
parenchyma, although an indirect method has recently been
presented (4).
The more permeable the BBB is to the drug, the quicker
the drug will reach the brain tissue. But it is not permeability
alone that is important regarding drug delivery to the brain
(5,6,17,18). The brain pharmacokinetics of a centrally acting
drug, and thereby its associated pharmacodynamics, are the
result of a combination of influx and efflux processes plus
the extent of distribution of the drug within the brain tissue.
The rate of delivery (which is dependent on the permeability
of the BBB) must be considered separately from the extent of
equilibration of the drug across the BBB and the intra-brain
distribution data in order to fully understand brain drug
delivery and its consequences for central drug action.
This paper looks at the different aspects of drug delivery
to and distribution within the brain, ranging from the basic
physiological properties to an outline of the relevant param-
eters for describing the processes, with examples. The focus
of the article is on comparisons between brain tissue and
blood, across the BBB, as this is the main surface area for
exchanges between these compartments.
BASIC CONCEPTS AND METHODS
The BBB and Brain Tissue Physiology
In order to understand drug transport and distribution
in the CNS, it is important to have a clear picture of the
physiological volumes and flow rates of the brain fluids.
Interpretation of experimental results is often not possible
without taking these characteristics into account. Table I lists
several of the relevant physiological parameters and values
from the literature for the rat, as this species is often used in
drug discovery and development.
The BBB is not just a passive membrane separating
blood from brain parenchyma, but is an active organ with
important functions for brain homeostasis and protection.
This organ consists of the endothelial cells comprising the
capillaries present throughout the brain parenchyma (Fig. 1).
The tight junctions form the basis of the mode of action of the
BBB. Apart from metabolic functions, there are numerous
transporters governing influx and efflux of endogenous and
Table I. Collated Information from the Literature on Physiological Values Relevant to Drug Transport and Distribution in the Rat Brain
Property Value Measurement Reference
Brain weight 1.8 g Rat 250 g (98)
Brain water content 0.788 ml/g brain (99)
Brain vascular space 14T1 2l/g brain Plasma, sucrose space (100)
1.3 (0.8–2.0) % v/v Plasma,
133mIn space (101)
6.4–23.2 2l/g brain Plasma, sucrose space (102)
34T4 2l/g brain Blood, hemodilution technique (103)
2.67T0.33 2l/g brain Blood, microwave fixation (104)
Cerebral blood flow 1.44T14 ml/min/g brain (103)
1.01T0.24 ml/min/g brain (104)
0.93 ml/min/g brain (105)
Mean transit time 2.8T0.8 s (106)
1.41T0.07 s (103)
Brain endothelial cell thickness (BBB) 200–500 nm (8,107)
Surface area of endothelial cells (BBB) 100 cm
2/g brain (108)
Volume of endothelial cells in brain 0.80 2l/g brain (109)
Distance between brain capillaries 50 2m (2)
Brain ISF volume 17–20% v/v (110)
13.5–14.5 ml/g brain (111)
0.21 ml/g brain (112)
Brain ISF bulk flow 0.18–0.29 2l/g brain (32)
0.11 2l/g brain (31)
CSF volume 250 2l (113)
CSF production rate 2.1–5.4 2l/min/brain (114)
2.9 2l/min/brain (115)
3.7T0.1 2l/min/brain (116)
2.2 2l/min/brain (117)
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the BBB, the compounds need to pass both the luminal
(facing blood) and the abluminal (facing brain ISF) mem-
branes of the endothelial cells. For example, the active efflux
transporters P-glycoprotein (Abcb1, Pgp) and breast cancer
resistance protein (Abcg2, Bcrp) are located in the luminal
membrane (25,26), while the organic anion transporter 3
(SLC22A8, Oat3) has been found in the abluminal membrane
(27), indicating differences in their function. The organic anion
transporting polypeptide 2 (SLC01B1, Oatp2) is present in
both membranes (28).
Distribution of hydrophilic molecules within the brain
involves the tortuous paths associated with diffusion through
the ISF, which surrounds the cellular elements, and resultant
longer times to equilibrium than would occur in more homo-
geneous surroundings (Fig. 2)( 29,30). Bulk flow of the ISF
occurs, especially through the perivascular spaces and axon
tracts, draining into the CSF (31–33). CSF is secreted by the
choroid plexus into the ventricles, and is drained out through
arachnoid villi into the lymphatics. Thus, it is likely that the
ISF bulk flow contributes to the passive elimination of drugs
from the brain parenchyma. The CSF is separated from the
blood by the blood–cerebrospinal fluid barrier (BCSFB) at
the choroid plexus epithelium. BCSFB transport is probably
of less quantitative importance than BBB transport with
regard to the distribution of the majority of drugs into brain
tissue and their subsequent effects (34–36). The ependyma
lining the ventricles allows diffusional exchange from the CSF
to the brain interstitium; however, the contribution of this
exchange to the overall distribution of drugs is likely to be
small, as it is only diffusional and is counteracted by the bulk
flow of brain ISF to the CSF. The diffusion distance from the
CSF to most brain tissue is also considerably further than
between the brain capillaries. Concurrent transport of a drug
across the BBB is likely to have a dominant effect on brain
tissue concentrations after systemic administration, given the
large area of the BBB and the short distances between brain
capillaries (Fig. 1).
If the BBB and the BCSFB are accepted as separate
barriers with respect to active drug transport, it cannot be
considered relevant to use CSF concentrations as a substi-
tute for brain ISF concentrations without first investigating
whether the concentrations and rates of distribution into
these compartments are similar (7,35,36). Comparisons
between brain ISF and CSF concentrations show that they
can indeed differ (34,35,37). It cannot, therefore, be taken for
granted that concentrations will be similar, even if this is the
case for some drugs. The pragmatic question here is how
large these differences in concentration–time relationships
between brain ISF and CSF can be while still allowing CSF
concentrations to provide a relevant indication of brain ISF
concentrations (36).
Pharmacokinetics of Brain Delivery and Distribution
of Drugs
In the blood, drugs are present in the unbound form but
may also be bound to plasma proteins and erythrocytes. The
free drug hypothesis postulates that the concentration of
unbound drug is the driving force for all distribution pro-
cesses. This implies that plasma protein binding has the role
of a bystander regarding distributional and pharmacodynamic
steady-state consequences, since it does not influence the
extent of transport across the BBB in terms of unbound drug
concentrations (38,39). However, since total plasma concen-
trations are generally used as a reference in pharmacokinetic
studies, estimates of plasma protein binding are essential
for sound interpretation of pharmacokinetic data, especially
when relating the results to the drug pharmacodynamics.
The unbound drug molecules equilibrate across the BBB
with those in the brain ISF (Fig. 3). Equilibration between
unbound and bound drug molecules also takes place in the
interstitial space, across brain cell membranes, and within the
cells. Thus, there are several equilibration processes occurring
simultaneously and all have an impact on how rapidly steady
state is attained between blood and brain concentrations
(Fig. 3). The slowest of these equilibrations will be the rate-
limiting step for the distribution of a given drug. For drugs
Fig. 1. Brain capillaries from human cerebellar cortex show how close
togetherthebraincapillariesformingtheblood-brainbarrier(BBB)are.
From Duvernoy et al.1 9 8 3( 119), with permission from the publisher.
Fig. 2. An electron micrograph of the rat cortex, showing interstitial
fluid in red (black in printed version), a dendritic spine (S) and a
presynaptic terminal (P). The black bar denotes 1 μm. From
Nicholson and Syková, 1998, with permission from the publisher (29).
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is often the BBB transport itself or the diffusion of drug
molecules within brain tissue (40).
The pharmacokinetics of brain delivery are further
complicated by active influx and efflux transport at the BBB.
The mechanisms by which efflux transporters act will influence
the brain pharmacokinetics in different ways (18,41,42). It has
been suggested that Pgp, the best known and, according to
current understanding, the most important efflux transporter
for exogenous substances, lowers brain drug concentrations
through two mechanisms: a gate-keeper function that pre-
vents molecules from entering the brain and an extrusion
mechanism via which molecules already present in the
cytoplasm of the BBB endothelial cells are transported back
to the blood (43–46). The effect on the brain concentration-
time profiles will depend on which of these two functions is
predominant (42). It has also been speculated that some
compounds are transported from the brain ISF into the
endothelial cells by abluminal transporters and thereafter by
luminal transporters from the BBB to the blood. Hence,
transporters located at the two membranes of the BBB may
work together to reduce or increase brain concentrations of
certain compounds (27,47).
Permeability of the BBB (Rate of Transport)
The rate of transport of a drug across the BBB is
estimated as the permeability surface area product, also
called the PS product, or the influx clearance (Kin,C L in). It
is measured in μl min
−1 g brain
−1 or μls
−1 g brain
−1. These are
clearance measurements and not rates per se. In situ and in vivo
methods of measuring influx clearances are well established
and include, for example, the brain uptake index (BUI; also
called the in vivo carotid artery injection technique) (48), the
in situ brain perfusion method (49,50), the i.v. injection
technique (51,52) and microdialysis (17,53–58). There are
several reviews of in situ methods in the literature (10,59,60).
Methods like the BUI and in situ brain perfusion are rapid
techniques that measure total concentrations of drug in the
brain at early time points after drug administration.
Methods for measuring the efflux clearance out of the
brain (Kout,C L out) have been developed more recently.
These include the brain efflux index (BEI) (61) and com-
bined data from microdialysis and measurements of total
brain concentrations using various methods (40,62–70). Efflux
parameters based on total brain concentrations alone repre-
sent the elimination rate constant (half-life) of the drug in
brain parenchyma.
Fig. 3. A schematic drawing of the equilibration of drug concen-
trations among blood, brain and CSF. BBB is the blood-brain barrier,
BCSFB is the blood CSF barrier, brain ISF is the brain interstitial
fluid and brain ICF is the brain intracellular fluid. Plasma concen-
trations include both bound and unbound drug, and total brain
concentrations include bound and unbound drug both in brain ISF
and intracellularly.
Fig. 4. Blood (empty circles) and brain concentrations (filled circles)
of a) unbound morphine, b) unbound M6G and c) unbound
oxycodone in rats. The drugs were administered as exponential
infusions over 240 or 120 min to obtain rapid steady state in blood.
Microdialysis probes were placed in the jugular vein and striatum.
See Table III for values. From Tunblad et al. 2004, 2005 and Boström
et al 2006, with permission from the publishers (68,69,83).
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these methods requires the researcher to make various
assumptions. The intracarotid artery injection, in situ brain
perfusion and i.v. injection techniques all involve the assump-
tion that transfer across the BBB is unidirectional during the
study. With the multiple pass methods (in situ brain perfusion
and i.v. injection techniques), it is also assumed that BBB
penetration itself is the slowest step and that any subsequent
distribution processes will be faster. These assumptions are
not necessary for microdialysis combined with whole brain
tissue concentration measurements at steady state and model-
ing of the data (40,67–70).
Influx and efflux clearances describe the net capacity of
the BBB to transport a substance into or out of the brain. The
presence of efflux transporters like Pgp or Abcg2 on the
luminal side decreases the permeability (net influx clearance)
compared with passive transport, while active influx increases
the permeability clearance compared with passive transport
(42,69). Elimination via metabolism withinthe brain isincluded
in the measurement of efflux clearance, as is the contribution of
the brain ISF bulk flow.
Extent of Drug Concentration Equilibration
between Brain and Blood
The amount or concentration of drug present in the brain
at steady state in relation to that in blood is an important
aspect of drug transport to the brain, as it describes centrally
acting concentrations over time. Brain concentrations are
generally compared with blood concentrations to estimate the
delivery of drug to the brain. This ratio can be described by
the partition coefficient, Kp:
Kp;brain ¼
AUC tot;brain
AUC tot;plasma
ð1Þ
where AUCtot is the area under the concentration–time curve
for total (bound and unbound) concentrations in brain or
plasma. AUC and steady-state concentration Css can be used
interchangeably in this equation as they measure the same
property. The value of Kp can vary widely with the rate and
extent of BBB transport and the affinity of the drug for brain
tissue components relative to plasma protein binding.
To compensate for differences in plasma protein binding,
the partition coefficient Kp,u compares total brain drug con-
centrations with plasma concentrations of unbound drug:
Kp;u;brain ¼
AUC tot;brain
AUC u;plasma
ð2Þ
where AUCu,plasma represents the AUC for unbound drug in
plasma, equal to fu,plasma* AUCtot,plasma, where fu,plasma is the
fraction of unbound drug in plasma. Kp,u includes both BBB
transportpropertiesandthebrain tissueaffinity.Thus, forboth
Kp and Kp,u, all drug present in the brain tissue is included in
the relationship, irrespective of whether it is located intra- or
extracellularly, or is bound or unbound (Fig. 3).
The pharmacologically active drug component and its
equilibration across the BBB can be investigated by measur-
ing unbound drug concentrations in the brain ISF (Fig. 3).
The ratio of unbound drug concentration in brain ISF to that
in blood is called the unbound partition coefficient (Kp,uu). It
is independent of protein binding in blood or binding to brain
tissue components (71).
Kp;uu;brain ¼
AUC u;brainISF
AUC u;plasma
ð3Þ
The brain ISF concentration, Cu,brainISF, is by definition a
measure of unbound drug. It can be described by:
VISF*dCu;brainISF
dt
¼ CLin*Cu;plasma
  CLout þ CLi ðÞ *Cu;brainISF þ CLi*Ci ð4Þ
Vi*dCi
dt
¼ CLi   Cu;brainISF   Ci

ð5Þ
where VISF is the physiological volume of brain ISF. Given that
more than one compartment is needed to pharmacokinetically
describe brain concentration time profiles, Vi and Ci are the
apparent volume and concentration, respectively, of a peripheral
compartment i,a n dC L i is the inter-compartmental clearance
(40,67–69,72).
At steady state, dCu,brainISF/dt =0 .I fCu,brainISF = Ci,
which can be assumed since Ci describes a hypothetical com-
partment, the relationship in Eq. 4 becomes:
CLin*Cu;ss;plasma ¼ CLout*Cu;ss;brainISF ð6Þ
The unbound partition coefficient Kp,uu is thus deter-
mined only by the net influx and efflux clearances CLin and
CLout, and not by any subsequent partitioning into brain cells:
Kp;uu;brain ¼
AUCu;brainISF
AUCu;plasma
¼
CLin
CLout
ð7Þ
The unbound drug concentration ratio between brain ISF
and blood at steady state (Kp,uu) gives a direct quantitative
description of how the BBB handles the drug regarding passive
transport and active influx/efflux. This ratio is determined by the
relationship between the influx and efflux clearances, according
to Eq. 7.C L in is the sum of all passive and active influx
clearances minus possible active efflux clearances. CLout is, as
mentioned earlier, the sum of all elimination clearances from the
brain, passive and active BBB transport, and possible metabo-
lism and elimination via the ISF bulk flow. If the relationship is to
describe BBB transport as such, the assumptions are made that
the drug is not eliminated to a significant degree by metabolism
within the CNS and that it is not transported via bulk flow to the
CSF. If these elimination pathways are quantitatively important,
Kp,uu still describes the in vivo steady-state ratio, but cannot be
used to determine BBB transport parameters.
If the BBB transport of a drug is dominated by passive
processes, the influx and efflux clearance rates will be similar,
with a resulting Kp,uu close to unity (Eq. 7). When a drug is
actively effluxed, CLout is larger than CLin,a n dKp,uu becomes
smaller than unity. When transport is dominated by active
influx, Kp,uu is larger than unity (17,18,69,73). The equi-
libration process between brain ISF and brain parenchymal
cells has its own rate (Fig. 3). If this process is the slowest step,
the time to equilibrium between brain ISF and blood will be
longer than if BBB transport is the rate-limiting step (5,42).
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The ratio of concentrations of drug in whole brain tissue
to those of unbound drug in brain ISF will vary according to
the affinity of the drug for brain tissue components. The
unbound drug volume of distribution in brain (Vu,brain)i sa
useful measure of drug distribution in the brain parenchyma
since it describes the relationship between the total drug
concentration in the brain and the unbound drug concentra-
tion in brain ISF. Vu,brain is measured in ml g brain
−1 (61,63):
Vu;brain ¼
Atot;brain   Vblood*Ctot;blood
Cu;brainISF
ð8Þ
where Atot,brain is the measured total amount of drug per g
brain including blood present in the brain, Vblood is the volume
of blood per g brain, and Ctot,blood is the total concentration of
drug in blood. Compensation for the amount of drug present in
brain capillaries increases in importance as the ratio of total
drug concentrations in brain to blood decreases (74). The
estimated vascular space in brain tissue depends on the
vascular marker used (Table I).
Distribution into brain tissue can be experimentally
determined in two ways. Equation 8 can be used for data
from microdialysis studies at steady state when both unbound
brain ISF and total brain drug concentrations are measured,
or using AUC values after a shorter infusion. The unbound
volume of distribution may also be estimated in vitro in brain
slice uptake studies (4,61). In this method, the brain tissue
slice is incubated at 37°C in an oxygenated buffer containing
the substance of interest. Concentration measurements are
thereafter made in the buffer (comparable to Cu,brainISF in
Eq. 8 and in the slice (giving Abrain, i.e. the amount in brain
excluding capillary blood content).
Vu,brain describes the distribution of drug inside the BBB,
irrespective of the brain to blood concentration ratio. It is
different from the so-called brain volume of distribution
calculated in the in situ brain perfusion or i.v. injection
techniques, which is defined as the concentration in brain
tissue at decapitation divided by the concentration in the
perfusion fluid or plasma (50,52). This latter definition of
volume of distribution is also used in positron emission
tomography (PET). In the present paper, the volume param-
eter used in in situ brain perfusion and PET techniques is
comparable to Kp.
Equations describing the physiological components of
Vu,brain and how they influence its numerical value can be
derived from the definition of Vu,brain (Eq. 8). If Abrain
describes the total amount of drug in blood-free brain tissue,
Eq. 8 can be reduced to:
Vu;brain ¼
Abrain
Cu;brainISF
ð9Þ
where Abrain (μmol g brain
−1) comprises the amount of
unbound drug in the ISF plus the amount of drug associated
with the cells:
Abrain ¼ VbrainISF   Cu;brainISF þ Vcell   Acell ð10Þ
VbrainISF and Vcell are the physiological fractional vol-
umes of the brain ISF and brain cells, respectively, in ml g
brain
−1, and Acell is the amount of drug associated with the
cells (μmol ml cell
−1). The distribution volume of unbound
drug in the cell, Vu,cell (ml ICF ml cell
−1) is also introduced, as
this relates Acell to the intracellular concentration of unbound
drug, Cu,cell (μmol ml ICF
−1):
Acell ¼ Vu;cell   Cu;cell ð11Þ
Incorporating Eq. 11 into Eq. 10 and dividing by
Cu,brainISF gives:
Vu;brain ¼ VbrainISF þ Vcell   Vu;cell  
Cu;cell
Cu;brainISF
ð12Þ
As can be observed in Eq. 12, if no drug binds to or enters
the brain parenchyma, Cu,cell is zero and Vu,brain becomes equal
to VISF, typically a value around 0.2 ml g brain
−1 (Table I).
From a physiological perspective, this is the smallest Vu,brain
possible. A value close to the brain water volume (0.8 ml g
brain
−1,T a b l eI) may indicate even distribution through the
whole brain tissue. Likewise, a Vu,brain larger than 0.8 indicates
that the drug has affinity to brain tissue. Thus, Vu,brain is a
measure of brain distribution that can be compared with
physiological volumes to improve understanding of how the
drug is distributed in and binds to brain tissue.
The fraction of unbound drug in the brain (fu,brain) can
be used in a manner similar to Vu,brain (3,7,12,75). It originates
from the perception that drug distribution within the brain
is largely dominated by nonspecific binding, which can be
determined by a brain homogenate binding technique (5,
75–77). The parameter fu,brain is therefore the fraction of
unbound drug in (undiluted) brain homogenate. The in vivo
interpretation in terms of actual unbound drug concentrations
in ISF is difficult since the intact brain has distinct compart-
ments i.e. the intra- and extracellular spaces. If, but only if,
the intra- and extracellular concentrations of unbound drug
are the same, the fraction of unbound drug in brain homo-
genate is equal to 1/Vu,brain. The advantage of using Vu,brain is
that it can be compared with physiological volumes and
thereby give a more realistic insight into drug distribution
within the brain.
It cannot be directly assumed that the concentration of
unbound drug in brain ISF equals that in brain ICF, as there
are also transporters in the brain parenchymal membranes
(24). A concentration gradient should in fact be expected for
basic and acidic drugs since the lower intracellular pH
initiates trapping processes. It is currently not possible to
directly measure intracellular unbound drug concentrations,
but indirect techniques are emerging from the combined use
of brain slice uptake experiments and binding studies in
homogenised brain (4). Because of the absence of plasma
proteins in the brain ISF and the small fraction of membrane
surface area that faces the ISF, drug binding in brain tissue
can be considered intracellular. Accordingly, the brain homo-
genate binding method measures intracellular binding and
allows Vu,cell to be estimated. When combined with Vu,brain,
from brain slice uptake methods, the ICF-to-ISF concentra-
tion ratio of unbound drug (Kp,uu,cell) can be calculated as:
Kp;uu;cell ¼
Cu;cell
Cu;brainISF
¼
Vu;brain   VbrainISF
Vcell   Vu;cell
ð13Þ
1742 Hammarlund-Udenaes, Fridén, Syvänen and GuptaIf the total amount of drug in the brain has been
obtained from an in vivo experiment, the unbound intracel-
lular concentration can be similarly estimated:
Cu;cell ¼
Abrain Vu;brain   VbrainISF

Vcell   Vu;cell   Vu;brain
ð14Þ
However, it should be remembered that this represents
the overall concentration of unbound drug in the ICF and
that individual values may differ between different cell types
or subcellular structures.
Half-Life in Brain
If one brain compartment is assumed, the half-life of a
drug in brain can be determined by the efflux clearance plus
the volume of distribution of unbound drug in the brain, as
for half-life calculations in the body. If elimination from the
brain is more rapid than elimination from plasma, the plasma
half-life will determine the half-life in the brain. If elimination
from the brain is slower than from plasma, the brain half-life
will be longer. As the brain is such a small part of the whole
body, and therefore will retain only a small percentage of
the total body concentrations, slow elimination processes in
the brain will influence blood pharmacokinetics to a limited
extent only. However, as the time from drug administration
increases, the blood half-life could theoretically be influenced
by a longer brain half-life as the respective contribution from
brain elimination increases.
A brain half-life that is longer than the systemic half-life
could also influence the value of the partition coefficient of
the drug in brain to that in blood, depending on the time of
measurement (78). It may be difficult to know when pseudo-
steady state has been reached after rapid drug administration.
Ideally, an infusion should be administered with an initial
bolus dose to find the relationship describing steady-state
partitioning into the brain.
Active efflux using the gate-keeper mechanism will not
alter the drug kinetics inside the brain; it only reduces the
number of molecules entering the brain (41,42). Inhibition of
a gate-keeper transporter will therefore not change the brain
half-life compared to when the gate-keeper mechanism is
active. On the other hand, inhibition of a transporter that
picks drug molecules from the endothelial cells or brain ISF
and transports them back to the blood will result in longer
half-lives in the brain. Inhibition experiments can therefore
give an indication of the dominant type of active efflux
mechanism at the BBB. This assumes that BBB transport,
and not intra-brain distribution or elimination from the body,
is the rate-limiting step.
Interaction Potential at the BBB
The potential change in brain concentrations due to drug
interactions at the BBB, or interaction potential, can be
measured quantitatively. The more efficient the efflux, the
greater is the potential for a clinically relevant interaction.
Quantification requires measurement of Kp,uu or a cor-
responding parameter (4,71,79).
The size of the interaction potential is given by the
inverse of Kp,uu. If no active transport takes place at the BBB,
there is no risk of interactions at this site and the “baseline”
value is 1, i.e. unbound drug concentrations in brain ISF and
blood are equal. The lower the Kp,uu, the higher the inter-
action potential. A Kp,uu of 0.5 indicates a maximal two-fold
increase in brain ISF concentrations if all active efflux is
blocked and a ratio of 0.1 will theoretically give a 10-fold
increase. The risk of a drug interaction at the BBB is also
increased if one transporter dominates the transport. As with
drug metabolism, if there are several transporters acting on
the drug there is less risk of clinical consequences if one of the
transporters is blocked. If a drug is actively transported into
the brain, the interaction works in the other direction, i.e.
decreased brain delivery of the drug when the influx
transporter is inhibited. If a drug is a substrate for both influx
and efflux transporters, the interaction potential for each
transporter is greater than indicated by the Kp,uu ratio.
The implications of a specific active efflux transporter in
this respect have been studied by Dagenais et al.( 79). They
investigated the “Pgp effect”, which describes the reduction
in permeability clearance in Pgp-deficient mice compared
with that in wild-type mice. This quantifies the impact of the
knocked-out transporter on the permeability clearance and is
a good measurement of the interaction potential for a specific
transporter, as long as the other transporters affecting the
drug are not upregulated.
The techniques used to study the interaction potential
can influence the result. Changes in permeability clearance in
studies of in situ brain perfusion in Pgp knock-out mice will
be the same as those estimating Kp,uu from unbound steady-
state ratios when the efflux is achieved with a gate-keeper
mechanism. The reason for this is that the gate-keeper
mechanism only affects the net influx clearance, i.e. the same
parameter that is measured to determine the Pgp effect (79).
However, the two methods will not give the same result if
active extrusion of molecules from the brain is inhibited, since
this mechanism will also affect the net efflux clearance,
causing Kp,uu and the Pgp effect to be influenced to different
extents (42).
EXPERIMENTAL FINDINGS IN RELATION TO BASIC
CONCEPTS
The purpose of this section is to illustrate the conse-
quences of different types of measurements on interpretation
of the results. Most of the experimental results are from
studies of opioids, as this group of drugs has been studied
extensively using several of the brain transport methods
reviewed here.
Permeability (Rate)
BBB permeability clearances of the various opioids span
almost a 20,000-fold range (Table II), which is nearly as wide
as that reported for drugs in general (80). Results using
microdialysis and in situ methods based on total brain
concentrations seem to be similar for the few drugs for which
both methods have been used. Various conclusions can be
drawn from these data. Oxycodone has the highest perme-
ability clearance rate (1910 μlm l
−1g brain
−1) while M3G has
the lowest (0.11 μlm l
−1 g brain
−1). Most opioids have higher
permeability clearances than morphine. Although it is a
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has a higher influx clearance than M3G. In spite of having
rather low influx clearances, it is clear that both morphine
and M6G are centrally acting. Loperamide is less active
centrally than morphine in spite of a higher permeability
clearance across the BBB.
Extent of Equilibration vs Intra-Brain Distribution
The 10-fold difference in influx clearance between
morphine and M6G could indicate that the extent of brain
delivery also differs between these drugs. Indeed, if total
brain concentrations are measured, this seems to be the case.
Morphine has a Kp ratio of 0.74, while that of M6G is 0.05
(Table III). As the protein binding of the two compounds in
blood is about the same, this difference is carried over into
Kp,u. However, the unbound concentration ratio Kp,uu is
similar at about 0.29 (Fig. 4, Table III). How can this be, and
what does it mean regarding the pharmacodynamics of
morphine and M6G? To interpret these results, the intra-brain
distribution of the two substances must be examined more
closely. The Vu,brain for morphine is 1.7–2.4 ml g brain
-1,w h i l e
that for M6G is 0.2 ml g brain
-1 (Table III). This indicates a
large difference in the way that the two compounds are
handled once they are inside the CNS (Fig. 3). The
difference in volume between the drugs can be interpreted to
mean that morphine distributes into the cells while M6G is
confined more to the ISF of the brain. With respect to
pharmacodynamic relationships, since the μ receptors that are
activated by opioids face the brain ISF, the unbound brain ISF
concentrations will be more important than those in the cells.
When the total brain tissue concentration is measured, the
M6G sample will be “diluted” by cells containing relatively less
M6G, while the morphine sample will not, as morphine is
present intracellularly to a larger extent. Thus, the 10-fold
difference in influx clearance between morphine and M6G will
not correlate with the similar extent of equilibration across the
BBB of morphine and M6G.
Other drugs can also be used to illustrate the relation-
ships. The influx clearance of the antiepileptic drug gabapen-
tin is 44 μl min
−1 g brain
−1. Its Kp,uu is 0.12, demonstrating a
high proportion of active efflux transport (Table III). Once
Table II. Permeability Clearances of Drugs at the Blood–Brain Barrier in Decreasing Order, Determined Using Different Methods
Drug Permeability clearance (CLin) 2l min
-1 brain
-1 Method Species Reference
Oxycodone 1910 Microdialysis Rat (69)
Fentanyl 1840T240 In situ brain perfusion Mice (79)
Methadone 417T58 In situ brain perfusion Mice (79)
Loperamide 98.6T17.3 In situ brain perfusion Mice (79)
Gabapentin 44T21 Microdialysis Rat (63)
Morphine 8.03T0.28 i.v. injection technique Rat (118)
14T1 Microdialysis Rat (67)
11.4 (9) Microdialysis Rat (83)
10.4T3 In situ brain perfusion Mice (79)
Baclofen 1.57T0.76 Microdialysis Rat (65)
M6G 0.11T0.01 i.v. injection technique Rat (100)
0.142T0.026 i.v. injection technique Rat (118)
0.35 (28) Microdialysis Rat (72)
1.66 (17) Microdialysis Rat (68)
DPDPE 0.547T0.293 In situ brain perfusion Mice (79)
M3G 0.11 (25) Microdialysis Rat (40)
0.14T0.02 i.v. injection technique Rat (100)
Values are given as ± SD or (RSE%).
Table III. Extent of Equilibration Across the BBB and Intra-Brain Distribution of Drugs in the Rat
Drug Kp,brain Kp,u,brain Kp,uu,brain Vu,brain ml g brain
j1 Reference
Baclofen 0.037 0.022 0.82T0.56 (65)
Codeine 4.0T1.0 1.06T0.12 3.6 (82)
Gabapentin 0.64 0.12 5.5 (63)
Morphine 0.54T0.065 0.65T0.093 0.29T0.07 1.7 (83)
0.74 0.51T0.18 2.35
a (37)
M6G 0.069T0.011 0.080T0.013 0.29 0.19T0.04 (68)
0.22T0.09 0.2T0.02 (72)
0.05 0.56T0.18 0.13
a (37)
M3G 0.08T0.02 0.25T0.02 (40)
Oxycodone 4.5T2.8 7.8T1.2 3.03 (0.038) 2.20T0.53 (69)
YM992 71T11 1.42T0.81 375T159 (77)
Kp is the partition coefficient describing total brain to total plasma concentration ratios, Kp,u is the partition coefficient describing total brain to
unbound plasma concentration ratios, and Kp,uu is the partition coefficient describing unbound brain ISF to unbound plasma concentration
ratios. Vu,brain is the relationship between total brain and unbound brain ISF concentrations.
aCalculated from AUC information in the article.
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tissue, with a Vu,brain of 5.5 ml g brain
−1, resulting in a
relatively unimpressive Kp of 0.64. In fact, most of the drug
resides intracellularly in the brain, due to active influx into
neuronal cells (4). The level of protein binding in blood is
very low (81).
Deguchi et al. showed that the influx clearance of the
GABAB receptor agonist baclofen was dramatically lower
than the efflux clearance (1.6 vs 70 μlm i n
−1 gb r a i n
−1)( 65).
The distribution volume of this drug in the brain was 0.82 ml g
brain
−1, showing even distribution through the brain
parenchyma. The authors estimated that the concentration of
total baclofen in brain was 27-fold lower than that of unbound
baclofen in plasma.
Codeine, with a Kp,uu of 1, appears to have predomi-
nantly passive, rapid transport across the BBB. Because of a
high affinity with brain tissue components, the Kp of codeine
is 4 (Table III). Movement across the BBB of the antide-
pressant agent YM992 also seems to be dominated by passive
transport. This agent has been reported to have a Kp,uu of
around unity, a Kp of 71 and a Vu,brain of 375 ml g brain
−1
(77). This also indicates that there is theoretically no upper
limit for the value of Vu,brain.
The high Kp of oxycodone is determined by both its
intra-brain distribution (Vu,brain is 2.2 ml* g brain
−1) and
active influx at the BBB (69). Its Kp,uu of 3 indicates three-
fold higher influx than efflux clearance, a very unusual finding
for a drug.
Enantiomers may also differ regarding their distribution
into the brain. Gupta et al. compared the extent of brain
distribution for the cetirizine enantiomers (71). The Kp values
of 0.22 and 0.04 for S-a n dR-cetirizine could indicate
enantioselective brain distribution. However, when the dif-
ferent components of Kp were measured, it was found that
the plasma protein binding of cetirizine was stereoselective.
Binding in the brain, measured by Vu,brain, was not different
and the cetirizine enantiomers had similar Kp,uu values,
indicating that Pgp in the BBB handles the enantiomers
similarly. Thus, the differences in Kp were solely caused by
differing plasma protein binding. Drawing conclusions about
stereoselective BBB transport based on Kp values could,
therefore, be misleading.
Half-Life
While the brain ISF and blood half-lives of some drugs
are similar [e.g. codeine (82)], the brain ISF half-life of several
drugs [e.g. morphine, M6G and M3G in rats (37,40,68,
72,83,84) and morphine in humans and pigs (85,86)] is longer
than that in blood. For drugs such as zidovudine which easily
permeate the BBB, the brain concentration-time profiles
generally parallel the blood concentration-time profiles (87).
Also atenolol, a drug that is considered to not permeate the
BBB, has parallel concentrations in brain ISF and in blood
(88). Oxycodone has similar half-lives in brain ISF and blood,
despite a Kp,uu value that is higher than unity (Fig. 4, 69).
Interaction Potential
Of the opioids studied using in situ brain perfusion,
loperamide and DPDPE had the largest interaction potential,
with “Pgp effects” of 10 and 12, respectively. This indicates
that, in Pgp-deficient mice, the transport of these drugs into
the brain is 10 and 12 times higher than in wild-type mice
(79). The associated ratio of 1.2 for morphine indicates a
minute risk of interaction with Pgp substrates; morphine is
also a substrate for probenecid-sensitive transporters (83).
Methadone is in the intermediate range in this respect, with a
ratio of 2.6 regarding its possible Pgp interaction (79).
Plasma concentrations of M3G do not differ at all when
the drug is administered with probenecid (40). However, the
twofold increase in unbound M3G brain concentrations on
addition of probenecid illustrates that in some cases it is not
possible to discover local drug interactions without local brain
concentration measurements. The 27-fold difference in con-
centrations of baclofen across the BBB with lower concen-
trations in brain than in plasma was totally abolished during
coadministration of probenecid, indicating the enormous
influence of probenecid-sensitive transporters on brain con-
centrations of baclofen, and thus the very large interaction
potential for this drug (65).
The BBB interaction between verapamil and cyclosporin
A has a potentially large impact on brain verapamil concen-
trations, and has been studied using PET (89–92). This
example illustrates another issue regarding the risk of clinical
drug interactions at the BBB. Cyclosporin A is currently one
of the most potent Pgp inhibitors on the market for human
use. Inspite ofthis,Hsiao et al. elegantly illustrated that clinical
doses of cyclosporin A are much lower than those needed to
block Pgp fully at the BBB (90). Therefore, in clinical practice,
cyclosporin A can approximately double verapamil brain
concentrations in spite of a much higher interaction potential.
This does not mean, however, that the interaction risk in other
organs can be discarded, as the interaction potential is
dependent on the activity of the specific influx and efflux
transporters in each organ.
Comparison of “Rate” and “Extent” as Indicators of Brain
Drug Delivery
Given the CLin, Kp and Kp,uu values for pharmaco-
logically active opioids in Tables II and III, the permeability
clearances between oxycodone and morphine differ 167-
fold, the Kp values differ six-fold and the Kp,uu values differ
10-fold. When comparing oxycodone and M6G, the perme-
ability clearances differ 1,150-fold, the Kp v a l u e sd i f f e r9 0 -
fold and the Kp,uu values differ 10-fold. The corresponding
values for oxycodone and M3G are a 17,000-fold difference
in permeability clearance and a 30-fold difference in Kp,uu.
The differences in permeability clearance and unbound par-
tition coefficients between oxycodone and M3G are probably
in the maximal range possible, given the very high perme-
ability of oxycodone and the very low permeability of M3G,
and also the dominating active influx of oxycodone and the
low Kp,uu of M3G.
The potential difference in BBB permeability between
CNS drugs is thus several orders of magnitude greater than
the potential difference in unbound concentration ratios
between brain and blood. The possible range of differences
between potential CNS drugs in total brain concentrations
(Kp or Kp,u) is also much greater than for Kp,uu, as lipophilic
drugs have a high affinity to brain tissue. A realistic estima-
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not differ more than those of oxycodone and M3G. This gives
a pharmacologically relevant range of 0.1–3 for Kp,uu values
(a 30-fold difference) for drugs that are potentially adequately
delivered to the brain, given that one compound is actively
taken up by the brain at the BBB. If baclofen is included, the
range is 150-fold (0.02–3) (65).
DISCUSSION
This paper defines the factors of importance for deter-
mining and predicting drug delivery to the brain. The purpose
of the paper was to demonstrate the firm theoretical and
experimental in vivo basis on which informed decisions may
be based when designing and testing new drug candidates.
The purpose was also to review which parameters are actually
measured in in vitro, in situ and in silico methods, the inter-
relationships of these parameters, and the manner in which
they are related to clinically relevant parameters. Distinctions
between the various BBB transport and brain delivery
parameters may help to explain why good predictive in vitro
models have not yet emerged.
The parameters needed for a full description of delivery
of drugs to the brain are 1) the permeability clearance, 2)
the extent of equilibrium across the BBB, described by
the ratio of unbound concentrations in brain ISF to those
in blood (Kp,uu), and 3) the intra-brain distribution volume
(Vu,brain). With these three parameters, a clinically relevant
picture of brain drug delivery, covering both the rate and
extent, can be obtained.
The permeability clearance and other parallel measure-
ments such as the permeability surface area product (PS)
describe the rate of transport or, rather, the net influx clear-
ance across the BBB. This parameter, which can vary 20,000-
fold or more among drugs (80), is measured in cell culture
studies and in situ brain perfusion studies. The permeability
of the BBB to a drug is determined mainly by the drug’s
lipophilicity but is also influenced by the presence of active
transport processes at the BBB. If the BBB is highly perme-
able to a drug, the drug will be rapidly delivered into the
brain. Liu et al., however, showed that rapid brain equilibra-
tion is not the same as high BBB permeability, since a higher
level of nonspecific binding in the brain due to higher lipo-
philicity will increase the time to reach equilibrium (5).
Whether or not high permeability also results in high enough
concentrations for central action depends on the presence of
active efflux. Rapid permeation is also not necessarily a
prerequisite for a CNS effect, as drugs are in most instances
used continuously (6). A good example of an “impossible”
CNS drug in this respect is morphine, since permeation
through the BBB is low and it is actively effluxed.
The intra-brain distribution volume describes the accu-
mulation of drug inside the brain, or rather the nonspecific
binding to brain tissue components in relation to unbound
drug in brain ISF. Values reported for Vu,brain vary between
0.2 and 375 ml g brain
−1 (40,77), with a possibility of even
higher volumes for very lipophilic compounds, resulting in
potential for at least 2,000-fold differences in this parameter
between CNS-active drugs . The method recommended for
determination of intra-brain distribution is the brain slice
technique (3,4,61). Vu,brain can be directly compared on a
ml g brain
−1 basis to physiological volumes, thus directly
showing affinity and distribution. The fraction of unbound
drug in brain (fu,brain), which is usually similar to 1/Vu,brain,i s
a composite parameter representing intra- and extracellular
binding. This parameter is determined using the homogenate
method, the validity of which is compromised because cell
membranes are not intact (4).
The permeation of a drug through the BBB and its intra-
brain distribution are governed by similar physico-chemical
properties. It is therefore not surprising that, when rate and
extent methods based on total drug concentrations are used
to measure a parameter, the results are relatively well corre-
lated. In contrast, the extent of transport as being defined
here based on unbound drug concentrations is more deter-
mined by the balance of the processes at the BBB and less
by i.e. lipophilicity as such. Kp,uu can demonstrate directly
whether active efflux or influx is present, and the quantitative
importance of this transport. Kp,uu can also provide an indi-
cation of the interaction potential of a drug. It has thus far
been shown to vary between 0.02 and 3, i.e. a 150-fold
difference (65,69,93,94). The only possible in vivo method
for determining Kp,uu is microdialysis. In the early phases of
drug discovery, a reasonable estimation of Kp,uu can be
obtained from a combination of brain slice measurements to
give Vu,brain, total brain and plasma concentration measure-
ments at steady state (i.e. after 4 h of constant infusion), and
plasma protein binding measurements (4). Thus, if the extent
of BBB equilibration and the extent of plasma protein
binding are known for a drug, a plasma concentration mea-
surement can subsequently be translated into an unbound
brain concentration.
Total brain concentrations have historically been the
most common method of measuring CNS exposure. Thus,
development of a drug might be continued if it has a high
brain to plasma concentration ratio. However, high brain
concentrations are more an indication of high partitioning
into brain tissue than of pharmacologically active drug con-
centrations. The procedures in early drug discovery pro-
grammes may therefore be investigating the wrong targets.
Instead of investigating BBB permeability or total brain
concentrations, which can differ in value by several orders of
magnitude for known CNS drugs, the working range for
parameters such as the concentration ratios of unbound drug
across the BBB for an active CNS drug will be at most 150-
fold. Kp,uu is probably the most relevant parameter for pre-
dicting which drugs will be active in the CNS. For example,
the extent of BBB equilibration for antihistamines and loper-
amide is low, thus decreasing their potential for central side
effects versus peripheral effects. A high Kp,uu is preferential
when a central effect is desired. Thus, clinically relevant CNS
effects may be obtained even though the drug does not per-
meate the BBB well or is poorly bound to brain tissue (6), or
if the protein binding in plasma is high. If there are no
peripheral side effects, drugs undergoing extensive efflux
could also be considered for central action. If Kp,uu is low, it is
likely to be variable between individuals because of variations
in active transporter expression. A low Kp,uu also show a
higher likelihood of drug interactions at the BBB.
LogBB is often used in in silico models to predict BBB
permeability based on parameters such as the hydrogen bond-
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in vivo BB value is measured as the brain/blood drug concen-
tration ratio at a specific time point after drug administration
(15). According to the definitions in the present paper, logBB
is similar to Kp in that it is a measure of the extent of par-
titioning into brain, but is not necessarily measured at steady
state. The parameters measured to obtain in vivo logBB
values, which are then input into in silico logBB models,
include nonspecific binding to brain tissue, BBB equilibration
and plasma protein binding. However, BBB permeability,
which logBB purports to estimate, is not actually measured
with this technique. While correlations between logBB and
in vitro or in situ BBB permeability measurements may be
adversely affected because these measurements describe two
different aspects of brain drug delivery, both BBB permeability
and partitioning into brain tissue are governed by lipophilicity
and are therefore correlated with, for example, the solubility of
the drug in lipids and its hydrogen bonding properties. It could,
therefore, be speculated that logBB merely provides an in vivo
estimation of lipophilicity rather than the relevant brain
distribution estimations, especially in light of the three
parameters that are measured to reach logBB. Additionally,
the clinical value of a CNS compound is also determined by
the presence of active efflux or influx at the BBB. It is
therefore apparent that the physico-chemical descriptors
currently used in in silico models are not sufficient. Unfortu-
nately, information on transporters other than Pgp that might
be quantitatively important at the BBB is currently rudimen-
tary. What is, however, clear is that several drugs that are not
Pgp substrates are poorly transported into the brain (54,93),
probably because of active efflux rather than low permeability.
Expressions like “brain penetration” or “CNS penetra-
tion” can be defined based on either the rate or extent of
penetration. The extent of penetration can refer to either
total drug or unbound drug. As shown in the present paper,
the rate of penetration differs much more than the extent of
penetration between compounds. It has often been said that
some compounds are “unable to penetrate the BBB” or have
“no brain penetration”. In fact, brain penetration can be slow
(rate) or low (extent), but there will in most instances be drug
present in the brain ISF (17). For example, M6G, which
permeates the BBB slowly, has a Kp of 0.05 and a Kp,uu of
0.27 and is pharmacologically active in the CNS (37,68,72), is
illustrative of the problems with using this terminology to
understand effective brain drug delivery.
Pardridge suggested that “the BBB PS product predicts
the level of free drug in brain, because the level of free drug
is determined by: (i) the total drug concentration in plasma;
(ii) the PS product; and (iii), in the case of drugs bound by
plasma proteins, the fraction of drug in plasma that is bio-
available for transport into brain.” (15). However, the PS
product per se cannot predict the concentrations of unbound
drug in brain, as stated by Pardridge (15) and discussed by
Liu and Chen (6). Thus, the PS product cannot alone deter-
mine the extent of clinically relevant brain drug delivery.
Brain unbound drug concentrations are determined by plasma
unbound drug concentrations and Kp,uu, and similar Kp,uu
relationships can occur despite vastly different permeabilities
(17,18). It is also apparent that the PS product is a measure
of net influx clearance, i.e. its value is influenced by whether
the drug is associated with active influx or efflux (79). Studies
using knock-out animals can show the influence of a specific
transporter, given that the expression of other possible trans-
porters has not changed; however, for many drugs, we do not
yet know which transporters to look for.
A high level of plasma protein binding is in itself no
limitation for CNS action, as it can in theory be compensated
for by using higher doses. Binding to plasma proteins serve as
a depot of drug in the plasma. Thus, there is no need to
discard otherwise good lead candidates based on a protein
binding level above 95 % if other factors appear promising.
For example, although diazepam is highly plasma protein
bound (15), microdialysis experiments show that it has a Kp,uu
of 1 (38), i.e. unbound drug is distributed evenly between
brain ISF and plasma.
It has been suggested that the value of microdialysis is
lessened because of its invasive character (15,95–97). How-
ever, microdialysis is the only method currently available that
can directly measure brain concentrations of unbound drug
in vivo. Performed carefully, this method has much to offer in
terms of knowledge about BBB transport and the quantita-
tive influence of active transporters on the delivery of drugs
to the brain. It is therefore valuable as an in-depth method
for following local drug distribution. However, more rapid
methods are required in drug discovery programmes (3,4,6).
With a combination of in vitro and in vivo methods, it is
possible to efficiently map the clinically relevant properties of
new compounds, and the development of reliable in silico
methods for estimating brain drug delivery is continuing.
CONCLUSIONS
Relevant in vivo estimations of drug delivery to the brain
can be fully described using three parameters: CLin to
describe the permeability clearance into the brain, Kp,uu to
describe the ratio of unbound drug in brain to that in blood,
and Vu,brain to describe the intra-brain distribution. Methods
that measure these parameters can give clinically valuable
estimates of brain penetration early in the drug discovery
process, and can be used to correlate drug distribution with
pharmacodynamic evaluations in in vitro or in vivo systems.
A combination of measurements is suggested, as a single
rapid method cannot map all the important factors. The BBB
permeability per se is a less important predictor of drug
activity within the CNS than the extent of permeation, as
most drugs are administered on a continuous (repeated)
basis. Lower BBB permeability indicates slower transport
into the brain, but it may also indicate slower removal from
the brain. Low permeability issues for a potential drug may
be addressed by using dosage forms with slower release char-
acteristics. Among known CNS drugs, the ratio of brain ISF
to plasma unbound drug concentrations (Kp,uu) can differ by
a factor of up to 150-fold. This range is much smaller than
that for log BB ratios (Kp) which can differ by up to at least
2,000-fold, or for BBB permeabilities, which span an even
larger range (up to at least 20,000-fold). Thus, we need to re-
think the basis on which CNS drugs are selected and realize
that the range within which to work may be much smaller
than earlier comprehended. It is hoped that this paper will
provide inspiration for evidence-based consideration of the
choice of methods for determining successful brain penetration.
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